Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
Elon Musk Seeks $134 Billion in Lawsuit Against OpenAI and Microsoft Over Alleged Wrongful Gains 
Trump Criticizes NYSE Texas Expansion, Calls Dallas Exchange a Blow to New York 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
One Percent Rule Checklist For Safer Forex Trading Risk 
Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red 
Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion 
BHP Posts Record Iron Ore Output as China Pricing Pressures Loom 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
SAN DIEGO, April 24, 2017 -- Vical Incorporated (Nasdaq:VICL) today announced that it will host a virtual Research & Development Day for analysts, investors and media on Tuesday, May 2, 2017, beginning at 9:00 a.m. PT. This event will be available via webcast and conference call.
The event will provide a comprehensive overview of Vical’s product pipeline with an emphasis on the HSV-2 and invasive aspergillosis programs, including presentations by members of the Vical leadership team and two leading experts:
- Anna Wald, MD, MPH, Professor, Department of Medicine, Epidemiology and Laboratory Medicine at the University of Washington and Lead Investigator in the ongoing Phase 2 trial of Vical’s HSV-2 therapeutic vaccine candidate
- Haran Schlamm, MD, infectious disease specialist and former Senior Medical Director at Pfizer, responsible for clinical development, medical and regulatory affairs for Pfizer’s antifungal portfolio
Listeners may access the accompanying slide presentation through the webcast at www.vical.com. The call and webcast are open on a listen-only basis to any interested parties. To listen to the conference call, dial in approximately ten minutes before the scheduled call to (719) 325-2239 (preferred), or (888) 455-2308 (toll-free), and reference confirmation code 9084195. A replay of the call will be available for 48 hours beginning about two hours after the call. To listen to the replay, dial (719) 457-0820 (preferred) or (888) 203-1112 (toll-free) and enter replay passcode 9084195. The call also will be available live and archived through the events page at www.vical.com. For further information, contact Vical’s Investor Relations department by phone at (858) 646-1127 or by e-mail at [email protected].
About Vical
Vical develops biopharmaceutical products for the prevention and treatment of chronic or life-threatening infectious diseases, based on its patented DNA delivery technologies and other therapeutic approaches. Additional information on Vical is available at www.vical.com.
Contact: Tony Ramos (858) 646-1127 Website: www.vical.com
